



## General description

Imatinib is a BCR-ABL tyrosine kinase inhibitor used in treatment protocols for various leukaemias and solid tumours.

INN	Imatinib
ATC codes	L01EA01
Medicine type	Chemical agent
EML status history	<p>First added in 2015 (TRS 994) for Chronic myeloid leukaemia, not elsewhere classified</p> <p>Added in 2015 (TRS 994) for Gastrointestinal stromal tumour of unspecified gastrointestinal sites</p> <p>Added in 2021 (TRS 1035) for B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1</p>
Wikipedia	<a href="#">Imatinib</a> 
DrugBank	<a href="#">Imatinib</a> 

## Recommendations

### Section Targeted therapies

Oral > Solid: 100 mg; 400 mg

### Indications

Chronic myeloid leukaemia, not elsewhere classified

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

